Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-08-30
2011-08-30
Shaw, Amanda (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S024300, C536S023100
Reexamination Certificate
active
08008015
ABSTRACT:
Methods and kits for diagnosing the risk of developing restenosis after revascularization by implantation of stents based on the detection of single-nucleotide polymorphisms (SNPs).
REFERENCES:
Juppner, H. Functional Properties of the PTH/PTHrP receptor. Bone 1995 vol. 17 No. 2 pp. 39S-42S.
Pines, Jonathon et al. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. The EMBO Journal. 1994. vol. 13 No. 16 pp. 3772-3781.
Andres, Vicente, “Control of vascular cell proliferation and migration by cyclin-dependent kinase signaling: new perspectives and therapeutic potential”Cardiovascular Res. (2004) 63: 11-21.
Baz, et al., “Spanish Cardiac Catheterization and Coronary Intervention Registry. 17thOfficial Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2007)”Rev. Esp. Cardiol. (2008) 61(12): 1298-1314 (English Abstract Only).
Cogswell, et al., “Human cycline B1 gene, promoter region” Access No. U22364 in the GenBank database, May 16, 1995.
Costa, Marco A. and Daniel I. Simon, “Molecular Basis of Restenosis and Drug-Eluting Stent”Circulation(2005) 111: 2257-2273.
Dunham, et al., “Homo sapienschromosome 13, GRCh37 primary reference assembly” Access No. NC—000013 in the GenBank database, Jun. 10, 2009.
Dzau, et al., “Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies”Nature Medicine(2002) 8(11): 1249-1256.
Ekholm, Susanna V. and Steven I. Reed, “Regulation of G1cyclin-dependent kinases in the mammalian cell cycle”Current Opinion in Cell Biol. (2000) 12: 676-684.
Farina, et al., “Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NG-Y complex”Oncogene(1999) 18: 2818-2827.
Lazaro y de Mercado, Pablo, “Drug-Eluting Stents: Efficacy, Effectiveness, Efficiency and Evidence”Rev. Esp. Cardiol. (2004) 57(7): 608-612.
Massague, Joan, “G1 cell-cycle control and cancer”Nature(2004) 432: 298-306.
Monraats, et al., “Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions”Circulation(2005) 112: 2417-2425.
Monraats, et al., “Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention”Pharmacogentics and Genomics(2006) 16: 757-754.
Monraats, et al., “Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention”Genes and Immunity(2007) 8: 44-50.
Morishita, et al., “Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery”Gene(1994) 149: 13-19.
Nabel, Elizabeth G., “CDKS and CKIS: Molecular Targets for Tissue Remodelling”Nat. Rev. Drug Discovery(2002) 1: 587-598.
Rieder, et al., “Homo sapienscyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) gene, compete cds” Access No. AF497972 in the GenBank database, Apr. 11, 2002.
Rudez, et al., “Platelet Receptor P2RY12 Haplotypes Predict Restenosis After Percutaneous Coronary Interventions”Human Mutation(2008) 29(3): 375-380.
Santamaria, David, and Sagrario Ortega, “Cyclins and CDKS in development and cancer: lessons form genetically modified mice”Frontiers in Bioscience(2006) 11: 1164-1188.
Schmutz, et al., “Homo sapienschromosome 5, GRCh37 primary reference assembly” Access No. NC—000005 in the GenBank database, Jun. 10, 2009.
Sciortino, et al., “Thecyclin B1gene is actively transcribed during mitosis in HeLa cells”EMBO Reports(2001) 2(11): 1018-1023.
Serruys, et al., “Coronary-Artery Stents”N. Engl. J. Med. (2006) 354: 483-495.
Shaulian, Eitan and Michael Karin, “AP-1 in cell proliferation and survival”Oncogene(2001) 20: 2390-2400.
Wessely, et al., “Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar but Different”J. Am. College of Cardiology(2006) 47(4): 708-714.
Andres Garcia Vicente
Chaves Martinez Felipe Javier
Fernandez Aviles Francisco
Fernandez Ferri Patricia
Sanchez Fernandez Pedro Luis
Fina Biotech, S.L.U.
Knobbe Martens Olson & Bear LLP
Shaw Amanda
LandOfFree
Genetic markers of the risk of developing restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic markers of the risk of developing restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic markers of the risk of developing restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680949